| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/10/2001 | CA2388822A1 27 human secreted proteins |
| 05/10/2001 | CA2388657A1 New combination comprising a beta 2 (.beta.)2 adreno receptor agonist and a leukotriene receptor antagonist |
| 05/10/2001 | CA2388339A1 Cholesterol reducing sterol compositions, preparation and method of use |
| 05/10/2001 | CA2388333A1 Method and compositions for treating pulmonary diseases |
| 05/10/2001 | CA2388202A1 Polymorphic form of a tachykinin receptor antagonist |
| 05/10/2001 | CA2388187A1 Treatment of c. difficile toxin b associated conditions |
| 05/10/2001 | CA2388171A1 8-aza-bicyclo[3.2.1]octane nmda/nr2b antagonists |
| 05/10/2001 | CA2388159A1 Osmotic controlled release drug delivery device |
| 05/10/2001 | CA2388028A1 Method of inactivating pathogens |
| 05/10/2001 | CA2387808A1 Human chemokine beta-13 |
| 05/10/2001 | CA2387801A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | CA2387745A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | CA2387741A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | CA2387660A1 Diaryl-enynes as glycine transport inhibitors |
| 05/10/2001 | CA2387620A1 Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom |
| 05/10/2001 | CA2387613A1 Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them |
| 05/10/2001 | CA2387136A1 26 human secreted proteins |
| 05/10/2001 | CA2387135A1 Polymorphic forms of sertraline hydrochloride |
| 05/10/2001 | CA2386938A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 05/10/2001 | CA2386822A1 Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum |
| 05/10/2001 | CA2386641A1 32 human secreted proteins |
| 05/10/2001 | CA2385928A1 Agonists specific for the peripheral cannabinoid receptor |
| 05/10/2001 | CA2383992A1 Antibiotic sultam and sultone derived oxazolidinones |
| 05/10/2001 | CA2382455A1 Nucleic acids and proteins from group b streptococcus |
| 05/10/2001 | CA2358921A1 Oxetanone derivatives |
| 05/10/2001 | CA2358314A1 Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor |
| 05/10/2001 | CA2325201A1 Methods of administering apo b-secretion/mtp inhibitors |
| 05/10/2001 | CA2324813A1 Combination treatment for depression and anxiety |
| 05/10/2001 | CA2324801A1 Use of apo b secretion/mtp inhibitors and anti-obesity agents |
| 05/10/2001 | CA2324800A1 Use of apo b secretion/mtp inhibitors |
| 05/09/2001 | EP1097937A1 N-acyl derivatives of the LL-E33288 antitumor antibiotics |
| 05/09/2001 | EP1097927A1 Cyanoiminoquinoxaline derivatives |
| 05/09/2001 | EP1097926A1 Thiobenzimidazole derivatives |
| 05/09/2001 | EP1097922A1 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 05/09/2001 | EP1097921A1 Phenylhydrazines |
| 05/09/2001 | EP1097920A1 Intermediate for condensed benzazepine derivatives |
| 05/09/2001 | EP1097744A1 Polar solvent-in-oil emulsions and multiple emulsions |
| 05/09/2001 | EP1097720A1 Antiviral agent for use in treatment of cancer |
| 05/09/2001 | EP1097719A1 NEP inhibitors for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097718A1 NPY antagonists for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097714A1 Composition for use in the treatment of tumours and the immunization of humans and animals |
| 05/09/2001 | EP1097713A1 Inhibitors of the inositol polyphosphate 5-phosphatase ship-2 molecule |
| 05/09/2001 | EP1097712A1 Steroid-containing cataplasms and process for producing the same |
| 05/09/2001 | EP1097711A2 Treatment of pulmonary hypertension |
| 05/09/2001 | EP1097710A2 Combination product for treating niddm |
| 05/09/2001 | EP1097709A2 Use of corticotropin releasing factor antagonists for treating syndrome X |
| 05/09/2001 | EP1097708A1 Use of trans-trans isomers of conjugated linoleic acid |
| 05/09/2001 | EP1097707A1 Treatment of female sexual dysfunction |
| 05/09/2001 | EP1097706A1 Phosphodiesterase inhibitors for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097705A2 Process for the manufacture of a pulverous preparation |
| 05/09/2001 | EP1097698A2 Utilization of derivatives of tetrahydropyridines (or 4-hydroxypiperidines)-butylazols in the preparation of a medicament for the treatment of pain |
| 05/09/2001 | EP1097696A1 Composition containing waxes and an hydrophilic active unstable in an oxidizing medium and cosmetic use thereof |
| 05/09/2001 | EP1097382A2 Imidazoline receptor binding compounds |
| 05/09/2001 | EP1097238A1 Fermentation process to produce clavulanic acid at a low concentration of free amino acids |
| 05/09/2001 | EP1097210A1 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain |
| 05/09/2001 | EP1097202A2 Human transport protein homologs |
| 05/09/2001 | EP1097167A2 Neurotrophic growth factor |
| 05/09/2001 | EP1097162A2 Oligonucleotides having site specific chiral phosphorothioate internucleoside linkages |
| 05/09/2001 | EP1097159A1 Phosphinous and phosphonic acid derivatives used as medicaments |
| 05/09/2001 | EP1097154A1 Substituted benzimidazoles, production and use thereof as agents for combating parasitic protozoas |
| 05/09/2001 | EP1097153A1 Novel triazolo[4,5-d]pyrimidine compounds |
| 05/09/2001 | EP1097150A1 Imidazolyl derivatives |
| 05/09/2001 | EP1097149A1 Bicyclohexane derivatives |
| 05/09/2001 | EP1097148A2 Polymorph of ritonavir |
| 05/09/2001 | EP1097147A1 Novel angiogenesis inhibitors |
| 05/09/2001 | EP1097145A1 Polyhydroalkylpyrazine derivatives and their preparation and medicines containing them |
| 05/09/2001 | EP1097142A1 Phthalazine derivatives phosphodiesterase 4 inhibitors |
| 05/09/2001 | EP1097141A1 Imidazole derivatives with biphenylsulfonyl substitution, method for preparing them and their use as a drug or diagnostic agent |
| 05/09/2001 | EP1097140A2 Biphenylsulfonyl-substituted imidazole derivatives, their preparation process, their use as a drug or diagnostic agent and drug containing them |
| 05/09/2001 | EP1097139A1 Quinoline derivatives |
| 05/09/2001 | EP1097138A1 Pharmaceutical compositions comprising 2-quinolones |
| 05/09/2001 | EP1097137A1 N-substituted naphthalene carboxamides as neurokinin-receptor antagonists |
| 05/09/2001 | EP1097129A1 N-benzocycloalkyl-amide derivatives and their use as medicaments |
| 05/09/2001 | EP1097127A1 Diacylhydrazine derivatives as integrin inhibitors |
| 05/09/2001 | EP1096975A2 Methods for reducing intraocular pressure using a3-adenosine antagonists |
| 05/09/2001 | EP1096952A2 Polysaccharide vaccine for staphylococcal infections |
| 05/09/2001 | EP1096946A2 Delta cleavage products and methods based thereon |
| 05/09/2001 | EP1096944A1 Extracts of zanthoxylum bungeanum, pharmaceutical and cosmetic formulations containing them |
| 05/09/2001 | EP1096940A1 Biocompatible and biodegradable compositions containing hyaluronic acid and the derivatives thereof for the treatment of ulcers in the digestive apparatus |
| 05/09/2001 | EP1096939A1 Nocathiacin antibiotics |
| 05/09/2001 | EP1096938A1 Anti-irritant compositions containing a cyclic 2'-deoxy-nucleotide |
| 05/09/2001 | EP1096937A2 Sustained release ranolazine formulations |
| 05/09/2001 | EP1096936A1 Treatment of dyskinesia |
| 05/09/2001 | EP1096935A1 Medicinal product and method for treatment and prevention of dyskinesia |
| 05/09/2001 | EP1096934A1 Oxazolidinones to treat eye infections |
| 05/09/2001 | EP1096933A1 Use of an inhibitor of cytochrome p450 optionally combined with an antifungal agent for treating mycoses |
| 05/09/2001 | EP1096932A2 Antihypertensive combination of valsartan and calcium channel blocker |
| 05/09/2001 | EP1096931A2 Use of (s) (-)-amisulpride for the manufacture of a medicament for the treatment of schizophrenia |
| 05/09/2001 | EP1096930A1 Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents |
| 05/09/2001 | EP1096929A1 Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents |
| 05/09/2001 | EP1096928A1 New pharmaceutical preparation and method |
| 05/09/2001 | EP1096927A1 Composition for treatment of stress |
| 05/09/2001 | EP1096926A2 Methods and compounds for treating depression |
| 05/09/2001 | EP1096924A1 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 05/09/2001 | EP1096922A1 Improved stable topical ascorbic acid compositions |
| 05/09/2001 | EP1096921A1 Liposomal encapsulated nucleic acid-complexes |
| 05/09/2001 | EP1096919A1 Systems and methods for local delivery of an agent |
| 05/09/2001 | EP1096918A2 Skin and tissue care and/or treatment agent |
| 05/09/2001 | EP1066035A4 Substituted aromatic compounds for treatment of antibiotic resistant infections |
| 05/09/2001 | EP1033131A4 Composition of ingredients for a beverage having a delayed aversion effect |